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Oesophageal cancer incidence 
in 20-year follow-up in a 
population-based sample of 
12 000 middle-age men with 
or without Helicobacter pylori 
infection in Finland
Two consensus reports on Helicobacter 
pylori (Hp), published recently in Gut, 
summarise the role of Hp gastritis in 
upper GI diseases, including gastric cancer 
(GCA).1 2 Although Hp gastritis definitely 
increases the risk of GCA as suggested in 
both reports, Hp is, on the other hand, 
also associated with a notable low inci-
dence of oesophageal cancer (EC), of both 
adenomatous and squamous type.
In our earlier 15-year follow-up of a 
large population-based sample of males 
aged 50–65 years (n=12 016) from two 
Finnish cities, with or without Hp, diag-
nosed in 1994–1996 by serological (IgG) 
Hp test (Biohit HealthCare, Helsinki, 
Finland), 57 GCA cases were recorded in 
the study population by the nationwide 
Cancer Registry during the follow-up.3 Of 
these cancers, 50 were in men and seven in 
those with and without Hp, respectively. 
The relative standardised incidence ratio 
(RR) of GCA incidence in Hp positive 
compared with that in Hp-negative men, 
calculated with the Altman’s procedure, 
was 6.0 (95%CI 2.3 to 19.0).
In a 20-year follow-up of the same 
population sample, 39 ECs appeared 
during the follow-up. Of these, 29 were 
in the Hp-negative subgroup (6625 men) 
and 10 in the Hp-positive subgroup (5391 
men) (table 1). Of the cancers in Hp-neg-
ative and in Hp-positive subgroups, 11 
and three were ECs of adenocarcinoma 
type and 14 and six of squamous cell type, 
respectively. In five cases, the histological 
type was unknown. All estimates of RR of 
EC in the Hp-positive men compared with 
EC in the Hp-negative men were very low, 
as shown in table 1, indicating that the Hp 
gastritis associates strongly with reduced 
EC risk. In addition to ECs of adenocar-
cinoma type also, the RR of squamous cell 
EC was notably low (table 1). Serum level 
of pepsinogen I did not markedly alter any 
of the RR estimates.
The prevented fraction of EC due to 
Hp positivity was very high, 78%. In 
comparison, the corresponding attribut-
able percentage of GCA in Hp-positive 
men was 84%.3 Thus, relatively, the Hp 
gastritis reduces EC incidence roughly 
similarly as it increases GCA incidence. 
However, the incidence rate of GCA in the 
present study population was nearly twice 
as high as the incidence of EC. Therefore, 
the numbers of GCA caused by Hp posi-
tivity were nearly twice the numbers of EC 
prevented by Hp positivity.
Lower than the expected risk of oesoph-
ageal cancer in men with Hp gastritis has 
been presented in several other studies 
(see, eg, Nie et al, Rokkas et al, Islami and 
Kamangar, Xie et al, Ye et al, de Martel 
et al, Whiteman et al4–10) The reason of 
this low risk is unknown. So far, the most 
plausible explanation is the intragastric 
acidity that tends to be lower in patients 
with Hp gastritis than in those without 
it. In people with ‘healthy’ stomach, a 
highly acid gastro-oesophageal refluxate, 
in persons prone and liable to GERD, may 
promote cascades that result in acid-re-
lated erosive and finally cancerous lesions 
in the oesophageal epithelium. In this 
context, in contrast to alkaline reflux, the 
acid reflux into the oesophagus is likely 
the key factor that associates with the 
increased risk and incidence of EC.
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Correction notice this article has been corrected 
since it published Online First. the CI in the second 
paragraph has been updated to 6.0 (95% CI 2.3 to 
19.0).
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Table 1 Numbers and relative standardised incidence ratios (RR and 95% CI) of oesophageal cancer in Helicobacter pylori (Hp) antibody (HpAb) 
positive and negative middle-age men from two cities followed up by National Cancer Registry in Finland from 1994 to 1996 to 2014
Hp status
Risk ratio (RR) 95% CI of RR
Hp positive (≥30 HpAb (IgG) 
enzyme immunoassay unit)
Hp negative (<30 HpAb (IgG) 
enzyme immunoassay unit)








Number of cancers in follow-up by type of cancer
Adenomatous 3 11 0.22 0.05 to 0.95
Squamous 6 14 0.35 0.12 to 1.01
Other or unknown 1 4 − −
Total 10 (7)* 29 (28)* 0.28 0.13 to 0.60
*Numbers in brackets give the respective number of cases after excluding the men with atrophic gastritis (serum pepsinogen I <25 µg/L).
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